| Stereochemistry | ABSOLUTE |
| Molecular Formula | C17H19FN2O2 |
| Molecular Weight | 302.3434 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](NCC1=CC=C(OCC2=CC=CC=C2F)C=C1)C(N)=O
InChI
InChIKey=BHJIBOFHEFDSAU-LBPRGKRZSA-N
InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-6-8-15(9-7-13)22-11-14-4-2-3-5-16(14)18/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1
Priralfinamide, also known as Ralfinamide, FCE-26742A; NW-1029; PNU-0154339E, is a Na-channel blocker for the treatment of neuropathic pain and other pain conditions such as post-operative dental pain. It has a relatively complex pharmacology, acting as a mixed voltage-gated sodium channel blocker (including Nav1.7), N-type calcium channel blocker, noncompetitive NMDA receptor antagonist, and monoamine oxidase B inhibitor. Priralfinamide is in phase Ⅲ clinical trials by Newron for the treatment of chronic neuropathic pain.
CNS Activity
Originator
Approval Year
Doses
AEs
Sourcing
Sample Use Guides
Priralfinamide administered orally at rising doses of 80 - 320 mg/day
Route of Administration:
Oral
ACTIVE MOIETY
